MOU for Collaboration on Sleep Apnea Screening and Management
CE Certification for "Apnotrack," the Smartphone Diagnostic Assistant

Sleep artificial intelligence (AI) company A-Sleep is set to expand its sleep apnea screening and management business by partnering with global home healthcare company Air Liquide Healthcare.


On the 8th (local time), the Asleep-Air Liquide Healthcare business agreement ceremony was held in Paris, France. Asleep

On the 8th (local time), the Asleep-Air Liquide Healthcare business agreement ceremony was held in Paris, France. Asleep

View original image

On September 10, A-Sleep announced that it has signed a memorandum of understanding (MOU) with France's Air Liquide Healthcare to collaborate on sleep apnea screening and patient management. This agreement was signed during the AI collaboration session of the 'Korea-France Innovation Connect,' held in Paris, France on the 8th (local time), coinciding with the celebration of the 140th anniversary of diplomatic relations between Korea and France and President Lee Jaemyung's visit to France. The session introduced collaborative cases in the AI sector, such as those involving French AI leader Mistral AI and quantum computing company PASQAL, and highlighted healthcare collaborations between A-Sleep and Air Liquide Healthcare.


Air Liquide Healthcare is the healthcare division of France’s Air Liquide Group, established in 1902. The company provides home healthcare services to 2.3 million chronic disease patients across 30 countries and supplies medical gases and related services to approximately 20,000 hospitals and medical institutions. Last year, its healthcare division recorded sales of 4.4 billion euros. In Korea, the business operates through VitalAire Korea.


The two companies will first apply A-Sleep’s “Apnotrack” product to Air Liquide Healthcare’s domestic home patient management system. Apnotrack is an AI medical device that analyzes breathing sounds collected via a smartphone microphone during sleep, without the need for wearable equipment, to calculate the apnea-hypopnea index (AHI). When the user places the smartphone beside their pillow and falls asleep, the device analyzes the breathing sounds and sends results to dashboards used by healthcare professionals and service providers. According to the company, this enables early screening for sleep apnea even before formal diagnostic procedures for patients who might otherwise delay polysomnography—which typically requires an overnight hospital stay—due to the associated burden.


Because sleep apnea requires ongoing treatments such as positive airway pressure therapy even after diagnosis, long-term management and treatment adherence are crucial. Air Liquide Healthcare not only supplies positive airway pressure devices but also offers ongoing at-home patient management through in-person visits and adherence tracking services. Through this partnership, A-Sleep aims to support the entire continuum of home healthcare for sleep apnea, from initial screening using Apnotrack to therapy and post-treatment management.


The companies are also pursuing entry into the European market. In February, Apnotrack obtained CE certification (Class I) under the European Medical Device Regulation (MDR) and is undergoing initial validation in the local market. Both companies will assess the potential application of Apnotrack in various European countries where Air Liquide Healthcare conducts business.


Apnotrack has obtained approval from the Ministry of Food and Drug Safety and has been designated as an innovative medical device, with a non-reimbursable prescription code that allows for private health insurance claims. Within eight months of its launch in January this year, it has been prescribed by more than 600 medical institutions nationwide, and about half of the country’s tertiary general hospitals are in the process of adopting it. Domestic distribution is handled by Chong Kun Dang Pharmaceutical.



Dongheon Lee, CEO of A-Sleep, stated, "Sleep apnea is a condition where effective treatment requires ongoing therapy, not just a diagnosis. We plan to establish the first case in Korea in partnership with Air Liquide Healthcare, which has a track record of operating home healthcare in 30 countries, and then expand this initiative to several European countries."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing